What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures

2016 ◽  
Vol 113 (7) ◽  
pp. 796-803 ◽  
Author(s):  
Guillaume Passot ◽  
Delphine Vaudoyer ◽  
Laurent Villeneuve ◽  
Vahan Kepenekian ◽  
Annie-Claude Beaujard ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Curative Treatment ◽  
Peritoneal Surface Malignancy ◽  
Peritoneal Surface

scholarly journals Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy—current perspectives

2016 ◽  
Vol 23 (3) ◽  
pp. 266 ◽  
Author(s):  
J. Spiliotis ◽  
E. Halkia ◽  
E. De Bree
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Abdominal Cavity ◽  
Gastrointestinal Surgery ◽  
Morbidity And Mortality ◽  
Peritoneal Surface Malignancy ◽  
Perioperative Morbidity ◽  
Cancer Management ◽  
Peritoneal Surface ◽  
Crs And Hipec

Peritoneal carcinomatosis (PTC) represents advanced malignant disease and has generally been associated with a grim prognosis. Peritoneal surface malignancy is often the major source of morbidity and mortality; it is of major concern in cancer management. Although PTC is categorized as metastatic disease, it represents a special disease pattern considered to be a locoregional disease limited to the abdominal cavity. The combination of cytoreductive surgery (CRS) and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has successfully been used as locoregional treatment for selected patients with PTC from gastric, colorectal, and ovarian cancer; with mesothelioma; and with pseudomyxoma peritonei. In the prophylactic setting, HIPEC can also be used to prevent PTC in high-risk patients, and the first results of the “second-look” approach are promising. Patient selection—in which the risks of perioperative morbidity and mortality, which are analogous to those for any other major gastrointestinal surgery, are assessed—is of utmost importance. Those risks have to be weighed against the anticipated survival benefit, which depends mainly on tumour biology, extent of disease, and probability of achieving complete CRS. The present review discusses the principles of CRS and HIPEC, the most significant recent clinical data, and current perspectives concerning the application of this treatment modality in various malignancies. Ongoing trials and future directions are noted. It appears that the combination of CRS and HIPEC is an indispensable tool in the oncologist’s armamentarium.

scholarly journals Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2471
Author(s):  
Philipp Horvath ◽  
Can Yurttas ◽  
Stefan Beckert ◽  
Alfred Königsrainer ◽  
Ingmar Königsrainer
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
University Hospital ◽  
Peritoneal Surface Malignancy ◽  
Treatment Protocols ◽  
Primary Tumors ◽  
Peritoneal Surface ◽  
Group 2 ◽  
Group 1

(1) Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provide survival benefits to selected patients. We aimed to report our experience and the evolution of our peritoneal surface malignancy program. (2) Methods: From June 2005 to June 2017, 399 patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at the Tübingen University Hospital were analyzed from a prospectively collected database. (3) Results: Peritoneal metastasis from colorectal cancer was the leading indication (group 1: 28%; group 2: 32%). The median PCI was 15.5 (range, 1–39) in group 1 and 11 (range, 1–39) in group 2 (p = 0.002). Regarding the completeness of cytoreduction (CC), a score of 0 was achieved in 63% vs. 69% for group 1 and 2, respectively (p = 0.010). Median overall survival rates for patients in group 1 and 2 for colon cancer, ovarian cancer, gastric cancer and appendix cancer were 34 and 25 months; 45 months and not reached; 30 and 16 months; 39 months and not reached, respectively. The occurrence of grade-III and -IV complications slightly differed between groups (14.5% vs. 15.6%). No 30-day mortality occurred. (4) Conclusions: Specialized centers are able to provide low-morbidity cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without mortality. Strict patient selection during the time period significantly improved CC scores.

scholarly journals Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms

2015 ◽  
Vol 22 (2) ◽  
pp. 100 ◽  
Author(s):  
P. Dubé ◽  
L. Sideris ◽  
C. Law ◽  
L. Mack ◽  
E. Haase ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Collaborative Group ◽  
Peritoneal Surface Malignancy ◽  
Access To Treatment ◽  
Peritoneal Surface ◽  
Appendiceal Neoplasms ◽  
Patient Representatives ◽  
Peritoneal Surface Malignancies

To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved.Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres.The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.

Sign in / Sign up

Export Citation Format

Share Document